Status:
COMPLETED
Validation Study of the Korean Version of the EORTC QLQ-HDC29
Lead Sponsor:
Seoul National University Hospital
Conditions:
Quality of Life After Stem Cell Transplantation
Eligibility:
All Genders
18-80 years
Brief Summary
The aim of this study is to evaluate the reliability and validity of the Korean version of the European Organization for Research and Treatment of Cancer High-dose Chemotherapy module (EORTC HDC-29).
Eligibility Criteria
Inclusion
- Patients who are aged more than 18 years
- Patients who are diagnosed with hematologic malignancies and who are planned to receive high-dose chemotherapy followed by allogeneic or autologous stem cell transplantation (SCT)
- Patients who agree with the informed consent
Exclusion
- Patients who are unable to complete the questionnaire due to the serious physical or psychological morbidity
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
226 Patients enrolled
Trial Details
Trial ID
NCT01208532
Start Date
September 1 2010
End Date
December 1 2013
Last Update
April 23 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea